Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Kyverna Therapeutics, Inc. (KYTX : NSDQ)

• Company Description    Kyverna Therapeutics Inc. is a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company's lead product candidate includes KYV-101. Kyverna Therapeutics Inc. is based in EMERYVILLE, Calif. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $5.39 Daily Weekly Monthly 20 Day Moving Average: 891,880 shares Shares Outstanding: 61.84 (millions) Market Capitalization: $333.33 (millions) Beta: 2.06 52 Week High: $13.67 52 Week Low: $5.36 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -22.89% -22.08% 12 Week -28.04% -29.79% Year To Date -42.66% -45.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5980 HORTON STREET SUITE 550 - EMERYVILLE,CA 94608 USA ph: 510-925-2492 fax: - investorrelations@kyvernatx.com https://kyvernatx.com

• General Corporate Information    Officers Warner Biddle - Chief Executive Officer and Director Christi Shaw - Executive Chairperson and Director Marc Grasso - Chief Financial Officer Fred E. Cohen - Director Sravan Emany - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 501976104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/11/26 Share - Related Items Shares Outstanding: 61.84 Most Recent Split Date: (:1) Beta: 2.06 Market Capitalization: $333.33 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.70 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.98 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 35.05% vs. Previous Quarter: 4.55% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -81.92 03/31/26 - -81.88 ROA 09/30/26 - - 06/30/26 - -63.74 03/31/26 - -64.87 Current Ratio 09/30/26 - - 06/30/26 - 9.06 03/31/26 - 8.15 Quick Ratio 09/30/26 - - 06/30/26 - 9.06 03/31/26 - 8.15 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 2.72 03/31/26 - 3.23 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.15 03/31/26 - 0.13 Debt-to-Capital 09/30/26 - - 06/30/26 - 13.07 03/31/26 - 11.26

Powered by Zacks Investment Research ©